Key Highlights
● Agilent shares closed at $170.75 on 9 October 2026, and the second data set's $175.20 mean target implies upside of about 2.6%.
● Market data shows a lower $171.82 consensus from 19 analysts, implying only about 0.6% upside, with targets from $135 to $195.
● Market data counts 15 Buy and four Hold ratings, while the second data set shows 11 Strong Buy, four Buy and seven Hold.
● Barclays raised its target to $195 from $175 on 7 October, and several brokers lifted targets in late August.
Agilent Technologies, Inc. (NYSE:A) is a constituent of the S&P 500. The shares closed at $170.75 on Friday 9 October 2026, leaving the consensus analyst target only slightly above the share price.
What Is the Latest Analyst Price Target?
Market data reports a consensus target of $171.82 from 19 analysts, with a high of $195 and a low of $135, implying upside of only 0.6%. The second data set reports a mean of $175.20, a median of $177.50, a high of $190 and a low of $155 from 22 analysts, though its target data was last updated on 28 September. The market data low of $135 comes from Jefferies' July initiation, while most recent named targets lie between $165 and $195. The second data set's figures imply upside of about 2.6%.
What Are Wall Street Analysts Saying?
Market data records fifteen Buy and four Hold ratings, and the second data set shows eleven Strong Buy, four Buy and seven Hold. Barclays raised its target from $175 to $195 on 7 October 2026. In late August, several brokers lifted targets, including Citigroup to $190, JPMorgan to $190, RBC to $185, Stifel, Bank of America, TD Cowen and Bernstein to $180, and Goldman Sachs to $175. UBS initiated at Neutral with $165 on 9 September, and Jefferies initiated at Hold with $135 on 9 July.
What Could Help the Stock Reach the Price Target?
Recent revisions have been upward, and the highest named target is $195. Market data reports third-quarter results on 26 August above consensus and a raised full-year earnings per share guidance range. Further positive revisions could lift the consensus. The consensus target suggests upside of about 2.6% from the closing price, though that outcome depends on many assumptions that may not materialise.
What Could Prevent the Stock Reaching the Target?
The implied upside is small, which means the shares already trade near the average target. UBS and Jefferies rate the shares neutral, and the low targets of $135 to $165 indicate some analysts see limited room. Life sciences instrument makers can face changes in customer spending, which may alter forecasts. Analyst targets are also frequently revised, and a target set months ago may no longer reflect current conditions.
What Should Investors Watch Next?
Items to watch include whether other brokers follow Barclays in raising targets.
Agilent's Share Price Already Sits Near Its Average Target
Agilent closed at $170.75 on 9 October 2026, with the second data set's $175.20 mean implying about 2.6% upside and market data's $171.82 consensus only about 0.6%. Recent revisions have been upward, led by Barclays' raise to $195 and late-August increases from Citigroup, JPMorgan, RBC and others, while UBS and Jefferies rate the shares neutral with targets of $165 and $135. With the shares already trading near the average target, further gains would depend on results beating forecasts and more positive revisions, and market data reports third-quarter results above consensus and a raised full-year earnings-per-share guidance range.






Please wait processing your request...